Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimozide

FDA-approved product (tablet, oral), marketed as Orap, Pimozide.

Registered studies
15
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pimozide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Tics
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diphenylbutylpiperidine derivatives
FDA pharmacologic class
Typical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

15registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimozide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimozide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Electrophysiological Effects of Potential QT Prolonging Drugs

    NCT05716854 · start 2023-03-21

    Registered record
    Registry ID
    NCT05716854
    Conditions
    Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    Interventions
    Clarithromycin; Pimozide; Placebo (Part 1); Moxifloxacin; Cobicistat; Moxifloxacin and Cobicistat; Placebo (Part 2)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-03-21
    Completion
    2023-06-13
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    InterventionClarithromycin; Pimozide; Placebo (Part 1); Moxifloxacin +3 more
    PhasePhase 1
    Registry statusCompleted

  • Treatment for Post Acute COVID-19 Syndrome

    NCT05507372 · start 2022-10-01

    Registered record
    Registry ID
    NCT05507372
    Conditions
    Tinnitus, Subjective
    Interventions
    Pimozide 1 MG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2023-12-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinnitus, Subjective
    InterventionPimozide 1 MG
    PhaseNot applicable
    Registry statusUnknown

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)

    NCT03272503 · start 2017-10-27

    Registered record
    Registry ID
    NCT03272503
    Conditions
    ALS; Amyotrophic Lateral Sclerosis
    Interventions
    Pimozide 2mg/day (current) or 4 mg/day (study initiation); Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-10-27
    Completion
    2020-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALS; Amyotrophic Lateral Sclerosis
    InterventionPimozide 2mg/day (current) or 4 mg/day (study initiation); Placebo Oral Tablet
    PhasePhase 2
    Registry statusUnknown

  • Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    NCT02600741 · start 2015-07-24

    Registered record
    Registry ID
    NCT02600741
    Conditions
    Schizophrenia
    Interventions
    Caregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine; Droperidol; Fluphenazine; Haloperidol; Loxapine; Perphenazine; Pimozide; Prochlorperazine; Thiothixene; Thioridazine; Trifluoperazine; Aripiprazole; Asenapine; Clozapine; Iloperidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07-24
    Completion
    2018-07-05
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCaregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine +19 more
    PhaseNot recorded
    Registry statusCompleted

  • Antipsychotic Induced Structural and Functional Brain Changes

    NCT02435095 · start 2015-05

    Registered record
    Registry ID
    NCT02435095
    Conditions
    Schizophrenia
    Interventions
    Maintenance treatment; Intermittent treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-05
    Completion
    2020-08
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionMaintenance treatment; Intermittent treatment
    PhasePhase 4
    Registry statusTerminated

  • A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS

    NCT02463825 · start 2015-04

    Registered record
    Registry ID
    NCT02463825
    Conditions
    Amyotrophic Lateral Sclerosis (ALS)
    Interventions
    Pimozide 2 mg per day; Pimozide 4 mg per day; Placebo (Lactose tablet)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2021-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis (ALS)
    InterventionPimozide 2 mg per day; Pimozide 4 mg per day; Placebo (Lactose tablet)
    PhasePhase 2
    Registry statusUnknown

  • Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    NCT02307396 · start 2015-02-01

    Registered record
    Registry ID
    NCT02307396
    Conditions
    Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    Interventions
    Olanzapine; Amisulpride; Risperidone; Haloperidol; Quetiapine; Perphenazine; Sulpiride; bromperidol; Zuclopenthixol; Thioridazine; Paliperidone; Ziprasidone; Benperidol; Fluspirilene; Pimozide; Perazine; Fluphenazine; Flupentixole; Sertindole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders
    InterventionOlanzapine; Amisulpride; Risperidone; Haloperidol +15 more
    PhasePhase 4
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • YouScript IMPACT Registry

    NCT02191358 · start 2014-10

    Registered record
    Registry ID
    NCT02191358
    Conditions
    Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-08
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED +9 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

    NCT01765829 · start 2012-11

    Registered record
    Registry ID
    NCT01765829
    Conditions
    Psychosis Nos/Other
    Interventions
    Discontinuation antipsychotic treatment; Antipsychotic treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2015-11
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis Nos/Other
    InterventionDiscontinuation antipsychotic treatment; Antipsychotic treatment
    PhasePhase 3
    Registry statusUnknown

  • Antipsychotics and Risk of Hyperglycemic Emergencies

    NCT02582736 · start 2012-04

    Registered record
    Registry ID
    NCT02582736
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2
    Interventions
    Olanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-12
    Enrolment
    725,489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder +1 more
    InterventionOlanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

    NCT00158223 · start 2004-10

    Registered record
    Registry ID
    NCT00158223
    Conditions
    Schizophrenia; Psychotic Disorders
    Interventions
    Pimozide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-10
    Completion
    2009-02
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Psychotic Disorders
    InterventionPimozide; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Pimozide Augmentation for Clozapine Partial Response

    NCT00374244 · start 2004-01

    Registered record
    Registry ID
    NCT00374244
    Conditions
    Schizophrenia
    Interventions
    Pimozide; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-01
    Completion
    2011-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPimozide; placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome

    NCT00004652 · start 1993-02

    Registered record
    Registry ID
    NCT00004652
    Conditions
    Tourette Syndrome
    Interventions
    pimozide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1993-02
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette Syndrome
    Interventionpimozide
    PhasePhase 2
    Registry statusCompleted